Stock Price Quote

BIOCON LTD.

NSE : BIOCONBSE : 532523ISIN CODE : INE376G01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE380.252.45 (+0.65 %)
PREV CLOSE ( ) 377.80
OPEN PRICE ( ) 377.40
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 68568
TODAY'S LOW / HIGH ( )374.80 384.15
52 WK LOW / HIGH ( )290.8 424.95
NSE380.352.4 (+0.64 %)
PREV CLOSE( ) 377.95
OPEN PRICE ( ) 377.00
BID PRICE (QTY) 380.35 (172)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2108997
TODAY'S LOW / HIGH( ) 374.60 384.25
52 WK LOW / HIGH ( )291 424.95
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 29-11 1978
Management Info
Kiran Mazumdar-Shaw - Chairman Siddharth Mittal - Managing Director
Registered Office

Address 20th Km,Hosur Road,Electronic City,
Bengaluru,
Karnataka-560100

Phone 080 2808 2808

Email corporate.communications@biocon.com

Website www.biocon.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

13Feb Biocon informs about presentation
Pursuant to Regulation 30 of the Securities and Exchange Board of India..
13Feb Biocon reports over five-fold jump in
Biocon has reported results for third quarter ended December 31, 2025 (Q..
13Feb Biocon moves up on reporting over five
Biocon is currently trading at Rs. 378.35, up by 3.10 points or 0.83% fr..
29Jan Biocon gets VAI status for Andhra Prad
Biocon has received a Voluntary Action Indicated (VAI) status from the U..
29Jan Biocon declines on getting VAI status
Biocon is currently trading at Rs. 364.20, down by 5.95 points or 1.61 %..

Financials

in Millions
QTR Dec 25 ANNUAL 25
Net Profit-7646093
Gross Profit -845 6609
Operating Profit 14814181
Net Sales 621322426

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  13242.00 (1.52%)
M.Cap ( in Cr)16989.34
Torrent Pharma (BSE)
peergroup  4260.45 (4.58%)
M.Cap ( in Cr)144192.99
Procter&Gamble Healt (BSE)
peergroup  5061.35 (1.72%)
M.Cap ( in Cr)8401.53
JB Chem & Pharma (BSE)
peergroup  1977.85 (4.50%)
M.Cap ( in Cr)31749.94
Alkem Laboratories (BSE)
peergroup  5480.30 (1.46%)
M.Cap ( in Cr)65525.21

Shareholding Pattern

FI/BANKS/INSURANCE 6.91%
PROMOTERS 54.45%
NON-INSTITUTION 16.45%
MUTUAL FUNDS/UTI 13.75%
GOVERNMENT 0%
FII 0%

About Biocon Ltd.

Biocon Ltd. was incorporated in the year 1978. Its today's share price is 380.25. Its current market capitalisation stands at Rs 61635.02 Cr. In the latest quarter, company has reported Gross Sales of Rs. 22426 Cr and Total Income of Rs.24980 Cr. The company's management includes Rajesh Umakant Shanoy, Atul Dhawan, Nicholas Robert Haggar, Rekha Mehrotra Menon, Bobby Kanubhai Parikh, Naina Lal Kidwai, Eric Vivek Mazumdar, Ravi Rasendra Mazumdar, Siddharth Mittal, Kiran Mazumdar-Shaw.

It is listed on the BSE with a BSE Code of 532523 , NSE with an NSE Symbol of BIOCON and ISIN of INE376G01013. It's Registered office is at 20th Km,Hosur Road,Electronic CityBengaluru-560100, Karnataka. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, SR Batliboi & Associates, SR Batliboi & Associates LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.